Inverse Regulation of EGFR/HER1 and HER2-4 in Normal and Malignant Human Breast Tissue
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Inverse Regulation of EGFR/HER1 and HER2-4 in Normal and Malignant Human Breast Tissue
Authors
Keywords
-
Journal
PLoS One
Volume 8, Issue 8, Pages e74618
Publisher
Public Library of Science (PLoS)
Online
2013-08-23
DOI
10.1371/journal.pone.0074618
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Abstract PD07-07: Prediction of antiproliferative response to lapatinib by HER3 in an exploratory analysis of HER2-non-amplified (HER2−) breast cancer in the MAPLE presurgical study (CRUK E/06/039)
- (2014) M Dowsett et al. CANCER RESEARCH
- Activated HER-receptors in predicting outcome of ER-positive breast cancer patients treated with adjuvant endocrine therapy
- (2012) Mathilde S. Larsen et al. BREAST
- Neuregulin-1-Mediated Autocrine Signaling Underlies Sensitivity to HER2 Kinase Inhibitors in a Subset of Human Cancers
- (2011) Timothy R. Wilson et al. CANCER CELL
- Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
- (2011) José Baselga et al. NEW ENGLAND JOURNAL OF MEDICINE
- HER-3 Overexpression Is Prognostic of Reduced Breast Cancer Survival
- (2010) Connie G. Chiu et al. ANNALS OF SURGERY
- Increased mortality in HER2 positive, oestrogen receptor positive invasive breast cancer: a population-based study
- (2010) C A Purdie et al. BRITISH JOURNAL OF CANCER
- An Activated ErbB3/NRG1 Autocrine Loop Supports In Vivo Proliferation in Ovarian Cancer Cells
- (2010) Qing Sheng et al. CANCER CELL
- Intratumoral Estrogen Disposition in Breast Cancer
- (2010) B. P. Haynes et al. CLINICAL CANCER RESEARCH
- Lapatinib Restores Hormone Sensitivity with Differential Effects on Estrogen Receptor Signaling in Cell Models of Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer with Acquired Endocrine Resistance
- (2010) A. F. Leary et al. CLINICAL CANCER RESEARCH
- Phase II, Randomized Trial to Compare Anastrozole Combined with Gefitinib or Placebo in Postmenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer
- (2010) M. Cristofanilli et al. CLINICAL CANCER RESEARCH
- Randomized Study of Lapatinib Alone or in Combination With Trastuzumab in Women With ErbB2-Positive, Trastuzumab-Refractory Metastatic Breast Cancer
- (2010) Kimberly L. Blackwell et al. JOURNAL OF CLINICAL ONCOLOGY
- Nuclear receptor co-activators and HER-2/neu are upregulated in breast cancer patients during neo-adjuvant treatment with aromatase inhibitors
- (2009) M Hauglid Flågeng et al. BRITISH JOURNAL OF CANCER
- The upgraded role of HER3 and HER4 receptors in breast cancer
- (2009) Angelos K. Koutras et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways
- (2009) Sandra E. Ghayad et al. INTERNATIONAL JOURNAL OF CANCER
- Down-regulation of epidermal growth factor receptor induced by estrogens and phytoestrogens promotes the differentiation of U2OS human osteosarcoma cells
- (2009) Luisa Salvatori et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor–Positive Metastatic Breast Cancer
- (2009) Stephen Johnston et al. JOURNAL OF CLINICAL ONCOLOGY
- Trastuzumab Plus Anastrozole Versus Anastrozole Alone for the Treatment of Postmenopausal Women With Human Epidermal Growth Factor Receptor 2–Positive, Hormone Receptor–Positive Metastatic Breast Cancer: Results From the Randomized Phase III TAnDEM Study
- (2009) Bella Kaufman et al. JOURNAL OF CLINICAL ONCOLOGY
- Tissue estradiol is selectively elevated in receptor positive breast cancers while tumour estrone is reduced independent of receptor status
- (2009) P.E. Lønning et al. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY
- Molecular characterization of aromatase inhibitor-resistant, tamoxifen-resistant and LTEDaro cell lines
- (2009) Selma Masri et al. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY
- The NRG1 gene is frequently silenced by methylation in breast cancers and is a strong candidate for the 8p tumour suppressor gene
- (2009) Y L Chua et al. ONCOGENE
- Activation of ErbB3, EGFR and Erk is essential for growth of human breast cancer cell lines with acquired resistance to fulvestrant
- (2008) Thomas Frogne et al. BREAST CANCER RESEARCH AND TREATMENT
- Evaluation of the prognostic and predictive value of HER family mRNA expression in high-risk early breast cancer: A Hellenic Cooperative Oncology Group (HeCOG) study
- (2008) A K Koutras et al. BRITISH JOURNAL OF CANCER
- A Central Role for HER3 in HER2-Amplified Breast Cancer: Implications for Targeted Therapy
- (2008) S. T. Lee-Hoeflich et al. CANCER RESEARCH
- HER-2 Gene Amplification, HER-2 and Epidermal Growth Factor Receptor mRNA and Protein Expression, and Lapatinib Efficacy in Women with Metastatic Breast Cancer
- (2008) M. F. Press et al. CLINICAL CANCER RESEARCH
- Crosstalk between the Estrogen Receptor and the HER Tyrosine Kinase Receptor Family: Molecular Mechanism and Clinical Implications for Endocrine Therapy Resistance
- (2008) Grazia Arpino et al. ENDOCRINE REVIEWS
- An optimised, highly sensitive radioimmunoassay for the simultaneous measurement of estrone, estradiol and estrone sulfate in the ultra-low range in human plasma samples
- (2008) Jürgen Geisler et al. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY
- Regulation of ERBB2 by oestrogen receptor–PAX2 determines response to tamoxifen
- (2008) Antoni Hurtado et al. NATURE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now